Please check your internet connection and try again.
# Mylotarg (gemtuzumab ozogamicin)
## Overview
Mylotarg is a targeted therapy, specifically an antibody-drug conjugate, that targets the CD33 antigen found on the surface of acute myeloid leukemia (AML) cells. It delivers a cytotoxic agent (ozogamicin) directly to these cells, leading to cell death.
## Primary Indications
* Treatment of newly diagnosed Philadelphia chromosome-negative (Ph-) acute myeloid leukemia (AML) in adults.
* Treatment of relapsed or refractory Philadelphia chromosome-negative (Ph-) AML in adults.
## Adult Dosing
**Newly Diagnosed Ph- AML:**
* **Induction:** 6 mg/m² on days 1, 4, and 7. If aplasia is not recovered, the dose can be repeated on days 8, 11, and 14.
* **Consolidation:** 3 mg/m² on days 1, 4, and 7.
* **Maximum dose per cycle:** 6 mg/m².
**Relapsed or Refractory Ph- AML:**
* **First relapse:** 6 mg/m² on days 1, 4, and 7.
* **Second or later relapse, or refractory disease:** 3 mg/m² on days 1, 4, and 7.
* **Maximum dose per cycle:** 6 mg/m².
Dosing may be adjusted based on patient tolerance and specific protocols.
## Pediatric Dosing
The safety and efficacy of Mylotarg in pediatric patients have not been established.
## Dose Adjustments
Dose modifications may be necessary based on toxicity, particularly related to myelosuppression and hepatotoxicity. Refer to specific prescribing information and institutional protocols for detailed guidance on dose delays, reductions, or discontinuation.
## Contraindications
* Hypersensitivity to gemtuzumab ozogamicin or any component of the formulation.
* Active severe hepatic impairment.
## Adverse Effects
**Common:**
* Febrile neutropenia
* Thrombocytopenia
* Anemia
* Nausea, vomiting
* Diarrhea
* Mucositis
* Rash
* Headache
* Fatigue
* Increased liver enzymes (AST, ALT, bilirubin)
**Serious/Life-threatening:**
* **Hepatotoxicity:** Including severe elevations in bilirubin and transaminases, particularly VOD/SOS (veno-occlusive disease/sinusoidal obstruction syndrome). Risk is increased in patients with prior stem cell transplant, elevated bilirubin, or hepatic impairment.
* **Myelosuppression:** Leading to neutropenia, thrombocytopenia, and anemia.
* **Infusion-related reactions:** Including fever, chills, rash, dyspnea.
* **Hemorrhage:** Particularly in patients with severe thrombocytopenia.
## Key Drug Interactions
* **Hepatotoxic agents:** Concurrent use with other medications known to cause hepatotoxicity may increase the risk of liver injury. Careful monitoring is essential.
* **Myelosuppressive agents:** Concurrent use with other myelosuppressive therapies may potentiate neutropenia, thrombocytopenia, and anemia.
## Monitoring
* **Complete Blood Counts (CBC) with differential:** Frequently, especially during induction and consolidation phases, to monitor for myelosuppression.
* **Liver Function Tests (LFTs):** Including bilirubin, AST, ALT, and alkaline phosphatase, before each dose and as clinically indicated, particularly for the risk of VOD/SOS.
* **Signs and symptoms of infusion-related reactions:** During and after infusion.
* **Signs and symptoms of bleeding:** Especially in patients with thrombocytopenia.
* **Renal function:** To assess for potential impact.
## Clinical Pearls
* Mylotarg is associated with a significant risk of VOD/SOS, which can be life-threatening. Early recognition and management are critical. Risk factors include prior stem cell transplant, elevated bilirubin, and hepatic impairment.
* Administer prophylactic agents for mucositis and consider other supportive care measures for myelosuppression.
* Infusion-related reactions can occur; monitor patients closely during and after administration.
* Refer to the full prescribing information for detailed guidance on dose modifications and management of toxicities.
***
*Disclaimer: This information is intended for clinical use and does not replace professional medical advice. Always consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions.*
